Patient Experience Registry for Adolescents and Adults with Hemophilia Treated with Marstacimab

What this Trial Is About

This research focuses on adults and adolescents diagnosed with hemophilia A or B who are treated with marstacimab, a human monoclonal antibody targeting the tissue factor pathway inhibitor TFPI. The study aims to understand patient preferences and treatment burden related to marstacimab when used as routine prophylaxis. Researchers also explore outcomes such as annual bleeding rates and joint status changes over a six-month period. The study is observational and sponsored by the Institute of Hematology & Blood Diseases Hospital in China. Participants receive marstacimab through subcutaneous injections, starting with a loading dose of 300 mg on the first day divided into two 150 mg injections. From the second week onward, patients receive 150 mg once weekly. The study includes three key visits the initial administration day, a follow-up at about 30 days, and another at around 180 days. Throughout, treatment adherence and administration details are recorded. During the study, patients complete questionnaires assessing their preferences for subcutaneous versus intravenous injections and the treatment burden after 1 and 6 months of marstacimab use. Researchers also monitor bleeding rates and joint health using ultrasound. The study involves regular follow-ups over six months to evaluate these outcomes, ensuring a comprehensive understanding of patient experiences and clinical effects while on marstacimab.

Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry